Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL: Pucotenlimab and MRG003 Induction in LA-HNSCC
NCT06959108Phase 2Recruiting
- Sponsor
- GORTEC
- Start
- Oct 2025
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pucotenlimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Objective Response Rate at 20 months. Started Oct 2025; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06959108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959108.